|
21.10.2016 17:10:00
|
Mallinckrodt plc -- Moody's: FDA Proposal to withdraw generic Concerta from the market would be negative for Lannett and Mallinckrodt
New York, October 21, 2016 -- Moody's Investors Service commented that the Food and Drug Administration's (FDA) proposal to withdraw approval of the Abbreviated New Drug Applications (ANDAs) for methylphenidate HCl ER tablets (the generic version of Concerta) is credit negative for Mallinckrodt International Finance SA (Ba3 stable) and Lannett Company Inc. (B2 stable). There is no change to either company's rating or outlook.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.